COMMUNIQUÉS West-GlobeNewswire

AscellaHealth Advances AscellaOne Technology Strategy, Names Asad Shoostry Chief Technology Officer
15/09/2026
BERWYN, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a technology-first pharmacy management solutions provider, today announces the appointment of Asad Shoostry as chief technology officer, strengthening the [...]
FDA Launches Expedited IND Pilot, Begins Accepting Applications
15/09/2026
Silver Spring, MD, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot . Accelerating clinical trial timelines [...]
Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program
15/09/2026
Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimester Dr. Gordon Sanghera CBE [...]
TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026
15/09/2026
Final Phase 1 data provide clinical validation of CBP/p300 as a novel therapeutic target for overcoming transcriptional resistance in NSCLC TT125-802 demonstrates monotherapy anti-tumor activity across biologically [...]
Hummingbird Bioscience Appoints Dr. James Garner as President
15/09/2026
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“ [...]
Profusa, Inc. Receives Nasdaq Compliance Determination
15/09/2026
Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The [...]
The Waqf Fund acquires UK retail property to fund charitable work for generations to come
15/09/2026
MANCHESTER, United Kingdom, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The Waqf Fund announced a key real estate acquisition as a charity endowment. The fund has completed the £1.9 million purchase of a prime freehold retail [...]
Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease
15/09/2026
Rekha Abichandani, M.D., appointed Chief Medical Officer Enrollment nearing completion in Phase 2 basket study of WAL0921; initial data from diabetic kidney disease cohorts to be presented in fourth quarter 2026 Data [...]
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
15/09/2026
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease [...]
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
15/09/2026
- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer and Shiva G. Fritsch [...]
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
15/09/2026
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission [...]
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
15/09/2026
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to [...]
VitalHub Announces Expansion of AI Capabilities with Launch of AI Scribe
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today the launch of VitalHub AI Scribe, an ambient clinical intelligence (“ACI”) solution that [...]
Art Meets Whiskey: Breckenridge Distillery Debuts Limited-Edition Collectors Series Release with Pat Milbery
15/09/2026
Limited-Edition Release Continues Distillery's Celebration of the Art of Blending Through Whiskey, Visual Art and Community BRECKENRIDGE, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery , one of the [...]
Juniper Biosciences Unveils JBS-002 and JBS-004, Advancing Two Late-Stage Diagnostic Programs to Registration Batch Manufacturing in the Fourth Quarter of 2026
15/09/2026
Prostate cancer and Alzheimer’s disease imaging programs position the Company for FDA submissions in 2027 across two of the fastest-growing segments in molecular imaging BEDMINSTER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE [...]
Satellos to Present at the 31st Annual Congress of the World Muscle Society
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today [...]
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
15/09/2026
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no [...]
Remedy Plan Therapeutics Announces Multiple Development and Corporate Milestones as First-In-Class Hyperbolic NAMPT Inhibitor, RPT1G, Advances in Phase 1 Dose Escalation Trial in AML/MDS
15/09/2026
Enrollment advances into Cohort 2 of Phase 1 trial of RPT1G in relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS) U.S. Food and Drug Administration accepts Investigational [...]
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
15/09/2026
Milestone continues the progress towards detection of all 20 amino acids by end of 2026 BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a [...]

Pages